- Home
- BBLG vs SILO Comparison
BBLG vs SILO Comparison
Compare BBLG & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBLG
- SILO
- Stock Information
- Founded
- BBLG 2004
- SILO 2010
- Country
- BBLG United States
- SILO United States
- Employees
- BBLG N/A
- SILO N/A
- Industry
- BBLG Industrial Specialties
- SILO Apparel
- Sector
- BBLG Health Care
- SILO Consumer Discretionary
- Exchange
- BBLG Nasdaq
- SILO Nasdaq
- Market Cap
- BBLG 2.7M
- SILO 4.3M
- IPO Year
- BBLG N/A
- SILO N/A
- Fundamental
- Price
- BBLG $3.95
- SILO $0.63
- Analyst Decision
- BBLG
- SILO
- Analyst Count
- BBLG 0
- SILO 0
- Target Price
- BBLG N/A
- SILO N/A
- AVG Volume (30 Days)
- BBLG 1.4M
- SILO 2.2M
- Earning Date
- BBLG 08-08-2025
- SILO 08-12-2025
- Dividend Yield
- BBLG N/A
- SILO N/A
- EPS Growth
- BBLG N/A
- SILO N/A
- EPS
- BBLG N/A
- SILO N/A
- Revenue
- BBLG N/A
- SILO $72,102.00
- Revenue This Year
- BBLG N/A
- SILO $1.86
- Revenue Next Year
- BBLG N/A
- SILO N/A
- P/E Ratio
- BBLG N/A
- SILO N/A
- Revenue Growth
- BBLG N/A
- SILO N/A
- 52 Week Low
- BBLG $3.42
- SILO $0.41
- 52 Week High
- BBLG $25.50
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- BBLG 41.63
- SILO 50.82
- Support Level
- BBLG $4.70
- SILO $0.60
- Resistance Level
- BBLG $6.75
- SILO $0.66
- Average True Range (ATR)
- BBLG 0.69
- SILO 0.04
- MACD
- BBLG -0.10
- SILO 0.02
- Stochastic Oscillator
- BBLG 5.90
- SILO 69.70
About BBLG Bone Biologics Corp
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.